Demonstrating disease activity in patients with rheumatoid arthritis

Basit Öğe Kaydı
dc.contributor.authorKarapolat, I.
dc.contributor.authorSertpoyraz, F.
dc.contributor.authorOncel, G.
dc.contributor.authorKobak, S.
dc.contributor.authorYalcin, M.
dc.contributor.authorKumanlioglu, K.
dc.date.accessioned2019-10-27T21:53:41Z
dc.date.available2019-10-27T21:53:41Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractAim: We aimed to investigate the relationship of fluor-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) with clinical, laboratory pa rameters and conventional radiographs in patients with rheumatoid arthritis (RA). Patients, material, methods: 25 patients with RA diagnosis were evaluated by sociodemo, graphic, clinical [duration of disease (year), the joints in which the complaints started, most recent joint involvement]; other parameters used in RA-specific clinical assessment [Steinbocker functional staging, disease activity score 28 (DAS 28 score), health assess, ment questionnaire score (HAQ score), general RA assessment (patients' and physicians' global assessment), patients' assessments of "pain and general health condition (visual analog scale)], laboratory, radiological [conventional radiology of hand and foot joints], positron emission tomography [F-18 FDG PET visual total score and maximum standardized uptake value (SUVmax) total score] parameters. Results: No significant correlation was detected between the F-18 FDG PET total score and SUVmax total score of the patients and clinical, laboratory, and radiological parameters (p > 0.05). There was no relationship between the cut-off values determined according to the disease activity and F-18 FDG PET/SUVmax total values (p > 0.05). Conclusions: In our study, no relationship was found between disease activity demonstrated by F-18 FDG PET/CT in RA patients and clinical, laboratory, and radiological parameters. F-18 FDG PET/CT appears to be a more sensitive method in demonstrating disease activity compared to other evaluated methods.en_US
dc.identifier.doi10.3413/Nukmed-0597-13-06en_US
dc.identifier.endpage249en_US
dc.identifier.issn0029-5566
dc.identifier.issn2567-6407
dc.identifier.issue6en_US
dc.identifier.pmid24081426en_US
dc.identifier.startpage244en_US
dc.identifier.urihttps://doi.org/10.3413/Nukmed-0597-13-06
dc.identifier.urihttps://hdl.handle.net/11454/47945
dc.identifier.volume52en_US
dc.identifier.wosWOS:000329560200007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofNuklearmedizin-Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectF-18 FDG PET/CTen_US
dc.subjectrheumatoid arthritisen_US
dc.subjectdisease activityen_US
dc.subjectDAS 28en_US
dc.subjectSUVmaxen_US
dc.titleDemonstrating disease activity in patients with rheumatoid arthritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu